Intensive LDL lowering with evolocumab reduced first heart attack or stroke in diabetes

Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes. Results were presented at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in JAMA.